Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from HC Wainwright

Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst

Summit Therapeutics Inc (NASDAQ:SMMT) and Akeso said ivonescimab, a PD-1xVEGF bispecific antibody, can extend patients' lives for EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) progressed after EGFR-TKI treatment.

Benzinga

Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker

The global biopharmaceutical landscape is rapidly evolving, driven by innovations targeting complex diseases like organ fibrosis and liver conditions. As companies push the boundaries of medical science, new therapies are emerging that promise to transform patient care and redefine market leadership in these critical areas.

Benzinga

Down 50% From Its Highs, This Analyst Thinks CoreWeave Stock Can Double From Here

CoreWeave’s sharp pullback may be setting the stage for a powerful rebound, according to H.C. Wainwright.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

1 Analyst Says the Selloff in CoreWeave Stock is Overdone. Is CRWV Stock a Buy Here?

CRWV is testing a Fibonacci retracement level on the charts after an upgrade from H.C. Wainwright and reports that Jane Street bought a 5.4% stake.

Barchart

Who Won and Who Lost in Nuclear Energy’s Q2 Earnings

From industry leaders to pre-revenue innovators, see which well-known nuclear energy stocks had the best and worst earnings performances in Q2.

MarketBeat

Catalysts Align: Archer Beats Estimates, Delivers Aircraft to UAE

Archer Aviation's strong Q2 results, highlighted by its first UAE aircraft delivery and a strong balance sheet, reinforce its path to near-term revenue.

MarketBeat

CoreWeave's AI Demand Surges But Expansion Spending Cuts Into Profitability

CoreWeave (NASDAQ:CRWV) shares tumbled on Wednesday after the AI-focused cloud computing provider posted mixed second-quarter results, highlighting surging revenue and backlog alongside margin pressures from an aggressive expansion plan.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Why Morgan Stanley Upgraded This Biotech Stock to a Buy

Ionis is shaping up to be one of the most compelling long-term growth stories in biotech today.

Barchart

Ultragenyx Represents 'Intriguing Buying Opportunity,' Despite Recent Setbacks

HC Wainwright assumed coverage on Ultragenyx Pharmaceuticals, Inc. (NASDAQ:RARE) on Monday, representing an attractive opportunity at current levels.

Benzinga

Why This Analyst Thinks MicroStrategy Stock Can Soar to a New Street-High Target of $680

TD Cowen believes MSTR can reach $680. Will shares hit that mark?

Barchart

This Underdog AI Stock Just Got a New Street-High Price Target

This underrated AI player just landed a fresh price target on Wall Street as its AI-driven defense technology draws investor interest.

Barchart

Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?

Nektar Therapeutics soared 157% after Rezpeg succeeded in a Phase 2b eczema trial. Analysts forecast huge upside—here’s why there could be more gains ahead.

MarketBeat

Is Archer Aviation Stock a Buy, Sell, or Hold on Trump’s Flying Car Executive Order?

Archer Aviation shares rallied on Trump’s executive order in favor of eVTOL technology. HC Wainwright sees significant further upside in ACHR stock.

Barchart

Analysts Say MicroStrategy Is a ‘Turbocharger.’ Should You Buy MSTR Stock Here?

MSTR shares are trading at a discount to consensus price targets in May 2025.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Plug Power Is Surging on New Financing. Should You Buy the Penny Stock Here?

Plug Power announced strong Q1 preliminary results, operational improvements, and a new credit agreement on Monday. But is that reason enough to buy PLUG shares?

Investors Business Daily

Coinbase Clears Earnings Estimates, Revenue Spikes 138%

Coinbase posts triple-digit earnings, revenue gains to crush Q4 expectations. COIN stock rebounds above key moving average.

MarketBeat

Analyst Upgrade Shows Over Double Bagger Potential for BigBear.ai

BigBear.ai recently received a massive price target increase from one Wall Street analyst. Is it time to get in on this small AI stock?

Investors Business Daily

Bitcoin Miner Iren Sees Target Hikes On Earnings; Bitcoin Rebounds Above $96k

Bitcoin miner Iren received price target hikes after reporting earnings, 28% spike in AI revenue. Bitcoin price rebounds above $96,000.

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

2 Penny Stocks That Wall Street Believes Can Soar Around 292% to 442%

Analysts believe these two penny stocks have outstanding long-term potential.

Benzinga

Mizuho Analyst Remains Bullish On The EV Sector; Finds Rivian Better Positioned

Mizuho analyst Vijay Rakesh reiterated his Buy ratings on Rivian Automotive, Inc (NASDAQ:RIVN) and the $65 price target. He saw RIVN as a pure play and a strong early mover in the EV market, focusing on the higher-growth SUV and light truck market and a robust commercial vehicle roadmap beginning with Amazon.Com, Inc. (NASDAQ:AMZN). Rivian is…

Benzinga

HC Wainwright Believes Ayala's Initial Cancer Data Is Encouraging

Ayala Pharmaceuticals Inc (NASDAQ:AYALA) reported data from Part A of its Phase 2 (RINGSIDE) trial evaluating AL102 in patients with desmoid tumors on Tuesday. At 16 weeks, one of 13 patients treated with AL102 demonstrated an unconfirmed partial response, which HC Wainwright believes signals encouraging initial activity. HC Wainwright reiterated the Buy rating on the…

Benzinga

HC Wainwright Finds 'Synergies In Treatment' For This Bipolar-Focused Stock

HC Wainwright initiated coverage on NRx Pharmaceuticals Inc (NASDAQ:NRXP) with a Buying rating and a price target of $2. Earlier today, the FDA declined to issue an Emergency Use Authorization for NRx's Zyesami for a subgroup of patients who also received Gilead Sciences Inc's (NASDAQ:GILD) remdesivir in addition to Zyesami. The analyst is bullish on: Significant potential for NRX-101 for…

Benzinga

HC Wainwright Sees Over 300% Upside In This Cancer-Focused Stock

HC Wainwright has initiated Theseus Pharmaceuticals Inc (NASDAQ:THRX) with a Buy rating and a price target of $22 (310% upside). The analysts see gastrointestinal stromal tumors (GISTs) treatment space reigniting with the entrance of a Theseus' pan-KIT inhibitor THE-630, with a high likelihood of 5L approval with earlier line potential. The analysts believe THE-630 can…

Benzinga

Analysts Still Believe Verrica's Ycanth Is Approvable Despite FDA Response Letter

Verrica Pharmaceuticals Inc (NASDAQ:VRCA) held a Type A meeting with the FDA regarding the path forward for the resubmission and potential approval of Ycanth (VP-102) for molluscum contagiosum. HC Wainwright says VP-102 was approvable, and at the time of the Complete Response Letter (CRL), Verrica had already engaged a potential alternate solution supplier. It reiterates…

Benzinga

Why Did HC Wainwright Downgrade Addex Therapeutics

Last week, Addex Therapeutics Ltd (NASDAQ:ADXN) terminated the Phase 2b/3 study evaluating dipraglurant as a potential treatment for dyskinesia associated with Parkinson's disease (PD-LID) due to the slow rate of patient recruitment. Addex is suspending its financial guidance. Hence HC Wainwright downgraded its rating to Neutral from Buy without a price target, as dipraglurant…

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.